BTK and B-cell chronic lymphocytic leukemia: BCR inhibitors, such as ibrutinib targeting BTK or the PI3K inhibitor idelalisib [12, 13] indirectly block T-cell signals by removing CLL cells from immune niches by interfering with their migration and adhesion [1, 14, 15].